Indaptus Therapeutics, Inc. (INDP) Monday announced positive data from ongoing Phase 1 Trial of Decoy20 in patients with solid tumors.
The shares are currently at $2.75, up 16.03 percent from the previous close of $2.37 on a volume of 46,341.
The company said the administration of Decoy20 in study participants at both higher and lower doses induced dozens of cytokines and chemokines, many of which have been associated with innate and/or adaptive immune responses. Additionally, the adverse events associated with Decoy20 are generally lower-grade and transient.
The data were featured in a poster presentation at the American Society of Clinical Oncology Annual Meeting on June 1 in Chicago, Illinois.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.